At this conference, Grade Gene showcased the "Pinjijin" based on the NGS second-generation sequencing platform ® Lung cancer 11 gene testing, Pinjijin ® Clinical testing products such as 32 gene testing, 168 gene testing, and 689 gene testing for solid tumors have attracted widespread attention from many attendees.

On the afternoon of April 7th, Dr. Lin Yunfu, Chairman and Chief Scientific Officer of Grade Gene, was invited to give a speech on the topic of "Application and Problems of ctDNA in Real time Cancer Monitoring" at the ctDNA/Methylation Marker Forum. He shared his insights and thoughts on "Clinical Targeted Drug Guidance of ctDNA in Tumor Detection and Its Application in MRD and Tumor Recurrence Monitoring" and the related issues currently faced in ctDNA detection in clinical practice, which benefited the audience and led a new chapter in tumor gene detection.

The CCTB Academic Conference successfully concluded with Grade Gene. Not only did we learn about the cutting-edge technologies and latest developments in the field of tumor gene testing, but we also allowed new and old customers to witness the innovative capabilities and research and development strength of Grade Gene. In the future, Grade Gene will uphold the mission of "assisting medical care and safeguarding health", promote resource collaboration and value sharing within the industry through continuous technological innovation and platform exploration, and strive to build the first brand of tumor gene testing in China. At the same time, we will continue to actively promote the development of the medical industry and assist in the transformation and application of research results in tumor gene testing technology!